Veracyte to Acquire Decipher Biosciences
Decipher's comprehensive portfolio of tests in urologic cancers leverage whole transcriptome analysis and proprietary machine learning algorithms to improve patient decision-making.
Category: Unknown Origin & Other Cancer Types
Unknown Origin & Other Cancer Types
Latest
Unknown Origin & Other Cancer Types
Latest
Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Unknown Origin & Other Cancer Types
Latest
Immunohistochemistry Test Detects ROS1 Protein in Cancer
The biomarker may provide a cost-effective and efficient means to identify elevated ROS1 protein expression in cancer.
Vigilant Biosciences Commences Studies of Oral Cancer Test
Vigilant Biosciences has launched patient enrollment for clinical studies of its OncAlert point-of-care qualitative assay in support of its premarket regulatory submission to FDA.
Read More
Oral Cancer Tests Capture Biomarkers Using Saline Rinse
The tests are based on technology that accurately measures CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels.
Read MoreBlood Test Holds Promise for Early Diagnosis of Cervical Cancers
Collaborators are set to carry out clinical validation of a blood test for the diagnosis of cancers linked to human papillomavirus.
Read MoreBladder Cancer Monitor Addresses Cancer Recurrence
The Cepheid test is now commercially available in Germany and cleared for commercial availability in all countries accepting the CE mark.
Read More
FDA Issues Warning about Ovarian Cancer Screening Tests
The agency is especially concerned about delaying effective preventive treatments for women who show no symptoms, but who are still at increased risk of developing ovarian cancer.
Read More
Vigilant Biosciences Receives Funds to Develop Oral Cancer Diagnostic
The 15-month grant from the National Institute of Dental and Craniofacial Research will fund the development of a diagnostic test that utilizes optical imaging in combination with an oral rinse to detect CD44.
Read MoreFrom the Editor: Screening Now!
The US Preventive Services Task Force recently issued updated recommendations for colorectal cancer screening, reinforcing its previous recommendation that adults aged 50–75 be screened for colorectal cancer.
Read More
Epigenomics Receives FDA Approval for Colorectal Cancer Screening Test
The first blood-based screening test for colorectal cancer will be made available in the United States under a joint commercialization agreement with Polymedco.
Read MoreDatabase of Sequenced Human Genomes Provided Free to Public
Ambry Genetics has pledged to break a hoarding data mold that it says hinders medical progress.
Read More
The Cologuard Process
Cologuard is designed to be patient- and physician-friendly, and is highly automated to support efficiencies in Exact Sciences’ lab.
Read MoreInside Track: Detecting Ovarian Cancer
In this month’s Inside Track, Nadia Altomare, CEO of Abcodia, discusses how her company’s test can lead to improved clinical outcomes.
Read MoreCedars-Sinai, GenomeDx Partner on Whole Genome Profiling
Cedars-Sinai Medical Center has partnered with GenomeDx Biosciences on the Decipher genomics resource information database, a clinical genomics data-sharing program that unites physicians with GenomeDx’s full genome profiling platform.
Read More
CDC Awards Over $22 Million to Expand Colorectal Cancer Screening
Grant recipients include 24 state health departments, as well as six universities and one American Indian tribe.
Read MoreFDA Grants PMA for Colorectal Cancer Mutation Test
A new molecular PCR test identifies KRAS mutations to aid in determining therapy for metastatic colorectal cancer.
Read More
RainDance Technologies Forms Hematologic Oncology Consortium
After its ASH 2014 debut, the RainDance HemOnc Consortium, an international panel of clinical research experts, will focus on developing assays for liquid biopsy research of myeloid disorders.
Read More